Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-04-2013 | Original Paper

Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis

Authors: Jia-yan Ni, Shan-shan Liu, Lin-feng Xu, Hong-liang Sun, Yao-ting Chen

Published in: Journal of Cancer Research and Clinical Oncology | Issue 4/2013

Abstract

Purpose

This meta-analysis was designed to compare the effectiveness of the combination of transarterial chemoembolization (TACE) and percutaneous radiofrequency ablation (PRFA) with that of TACE and PRFA monotherapy in hepatocellular carcinoma (HCC).

Methods

Randomized controlled trials were searched using various databases, and six studies were revealed on comparing TACE plus PRFA with TACE and/or PRFA alone for the treatment for HCC. Overall survival rate and recurrence-free survival rate were analyzed and compared. All statistic analyses were conducted using Review Manager (version 4.2.2.) from the Cochrane collaboration.

Results

Meta-analysis data revealed that TACE plus PRFA had significantly better effectiveness on 1- and 3-year overall survival rate(odds ratio [OR] 1-year = 4.61, 95 % confidence interval [95 % CI] 2.26–9.42, P < 0.0001; OR 3-year = 2.79, 95 % CI 1.69–4.61, P < 0.0001) and 3-year recurrence-free survival rate ([OR] 3-year = 3.00, [95 % CI] 1.75–5.13, P < 0.0001) than that of TACE and/or PRFA alone treatment. There was no significant difference between the combined therapy and monotherapy on 1-year recurrence-free survival rate ([OR] 1-year = 1.55, [95 % CI] 0.91–2.65, P = 0.11).

Conclusions

The data of our study indicate that the combination of TACE and PRFA has better effectiveness than that of TACE and PRFA monotherapy in the treatment for patients with HCC.

Bruix J, Sherman M (2005) Practice guidelines committee, American association for the study of liver diseases management of hepatocellular carcinoma. Hepatology 42:1208–1236PubMedCrossRef

Bruix J, Sala M, Llovet JM (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127:S179–S185PubMedCrossRef

Buscarini L, Buscarini E, Di Stasi M et al (1999) Percutaneous radiofrequency thermal ablation combined with transcatheter arterial chemoembolization in the treatment of large hepatocellular carcinoma. Ultraschall Med 20:47–53PubMedCrossRef

Chen MS, Li JQ, Zheng Y et al (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocelluar carcinoma. Ann Surg 243:321–328PubMedCrossRef

Cho YK, Kim JK, Kim MY et al (2009) Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 49:453–459PubMedCrossRef

Egger M, Smith GD, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedCrossRef

Ferenci P, Fried M, Labrecque D et al (2010) Hepatocellular carcinoma(HCC): a global perspective. J Clin Gastroenterol 44:239–245PubMedCrossRef

Germani G, Pleguezuelo M, Gurusamy K et al (2010) Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 52:380–388PubMedCrossRef

Higgins JP, Altman DG, Gotzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928PubMedCrossRef

Jarnagin W, Chapman WC, Curley S et al (2010) Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxf) 12:302–310

Kim KM, Kim JH, Park IS et al (2009) Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol 24:806–814PubMedCrossRef

Kim JW, Kim JH, Won HJ, Shin YM, Yoon HK, Sung KB, Kim PN (2012) Hepatocellular carcinomas 2–3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone. Eur J Radiol 81:e189–e193PubMedCrossRef

Li ZR, Kang Z, Qian JS, Zhu KS, Jiang ZB, Huang MS, Guan SH, Shan H (2007) Radiofrequency ablation with or without transcather arterial chemoembolization for management of hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 27:1749–1751PubMed

Livraghi T, Goldberg SN, Lazzaroni S et al (2000) Hepatocellular carcinoma: radiofrequency ablation of medium and large lesions. Radiology 214:761–768PubMed

Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442PubMedCrossRef

Marelli L, Shusang V, Buscombe JR et al (2009) Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unrescetable hepatocellular cancer. J Nucl Med 50:871–877PubMedCrossRef

Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K (2010) Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 116:5452–5460PubMedCrossRef

Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: globocan 2000. Int J Cancer 94:153–156PubMedCrossRef

Peng ZW, Zhang YJ, Liang HH, Lin XJ, Guo RP, Chen MS (2012) Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology 262:689–700PubMedCrossRef

Poon RT, Ngan H, Lo CM, Liu CL, Fan ST, Wong J (2000) Transarterial chemoembolization for inoperable hepatocellular carcinoma and post resection intrahepatic recurrence. J Oncol Surg 73:109–114CrossRef

Shen SQ, Xiang JJ, Xiong CL, Wu SM, Zhu SS (2005) Intraoperative radiofrequency thermal ablation combined with portal vein infusion chemotherapy and transarterial chemoembolization for unresectable HCC. Hepatogastroenterology 52:1403–1407PubMed

Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K (2009) Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology 252:905–913PubMedCrossRef

Tateishi R, Shiina S, Teratani T et al (2005) Percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1000 cases. Cancer 103:1201–1209PubMedCrossRef

Wang YB, Chen MH, Yan K, Yang W, Dai Y, Yin SS (2005) Quality of life of primary hepatocellular carcinoma patients after radiofrequency ablation. Ai Zheng 24:827–833PubMed

Wang W, Shi J, Xie WF et al (2010) Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int 30:741–749PubMedCrossRef

Wang N, Guan Q, Wang K et al (2011) TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis. Med Oncol 28:1038–1043PubMedCrossRef

Xu L, Li P, Chen MS, Pang XH, Gao HJ, Peng ZW, Liang HH, Zhang YJ, Li JQ (2008) Percutaneous radiofrequency ablation combined with other minimally invasive treatments for recurrent hepatocellular carcinoma after hepatectomy. Zhonghua Wai Ke Za Zhi 46:1617–1620PubMed

Yang JD, Roberts LR (2010) Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7:448–458PubMedCrossRef

Yang P, Liang M, Zhang Y, Shen B (2008) Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Adv Ther 25:787–794PubMedCrossRef

Yang W, Chen MH, Wang MQ, Cui M, Gao W, Wu W, Wu JY, Dai Y, Yan K (2009) Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatol Res 39:231–240PubMedCrossRef

Yuen MF, Chan AO, Wong BC et al (2003) Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. Am J Gastroenterol 98:1181–1185PubMed

Zhang Z, Wu M, Chen H, Chen D, He J (2002) Percutaneous radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Zhonghua Wai Ke Za Zhi 40:826–829PubMed

Zhao M, Wang JP, Li W, Huang ZL, Zhang FJ, Fan WJ, Zhang L, Li XS, Pan CC, Wu PH (2011) Comparison of safety and efficacy for transcatheter arterial chemoembolization alone and plus radiofrequency ablation in the treatment of single branch portal vein tumor thrombus of hepatocellular carcinoma and their prognosis factors. Zhonghua Yi Xue Za Zhi 91:1167–1172PubMed

Title: Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis
Authors: Jia-yan Ni
Shan-shan Liu
Lin-feng Xu
Hong-liang Sun
Yao-ting Chen
Publication date: 01-04-2013
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 4/2013
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-012-1369-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2013

Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization

Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy

Midkine mRNA level in peripheral blood mononuclear cells is a novel biomarker for primary non-small cell lung cancer: a prospective study

CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary

The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells

Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page